ASIT biotech is a clinical stage (Phase 3) biopharmaceutical company publicly listed on EURONEXT (Brussels & Paris).
ASIT biotech’s mission is to lead an evolution in allergy therapeutics by creating a new generation of highly effective and efficient immunotherapy options for respiratory and food allergies. Our goal is to generate breakthrough treatments that deliver rapid, recognizable improvement in the life of allergy patients, within weeks rather than months or years following treatment initiation.
- Finalization of the contribution of the medical imaging division of the DMS group to Asit Biotech Tuesday, 25 January 2022
- Service of the application for cassation by the Walloon Region against the judgment of the Court of Appeal Tuesday, 18 January 2022
- Signature of amende and restated contribution agreement Tuesday, 09 November 2021 All ASIT news